These results are in direct contradiction to those of other authors who have described high TGF-α and HB-EGF levels to be associated with a progressive disease and a shorter overall survival-OS lapse after NSCLC patients had been treated with gefitinib (Masago et al. 2008). The gene discussed is HBEGF; the disease is non-small cell lung carcinoma.